Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral azacitidine (CC-486) maintenance therapy in Japanese adults with AML in complete remission
jRCT2011210063Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing CC-486 Arm with Placebo Arm (2 arms). Primary endpoint: Relapse-free survival. Started Jan 2022; status: active, not recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2011210063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210063.